Wednesday, February 10, 04:28 am IST
| Feedback
Moneycontrol » News Center » Business » Business News

Want news about Pfizer to land in your mailbox?

Set an alert here

Experts see boom in pharma outsourcing due to eco crisis

Published on Tue, Nov 11, 2008 at 09:11   |  Updated at Wed, Nov 12, 2008 at 09:02  |  Source : CNBC-TV18

A little under 10% of the Indian pharma industry thrives on outsourcing. But experts believe this segment is in for some robust growth, thanks to the global economic slowdown. Now, global companies are eyeing India as a destination for outsourcing of manufacturing and research and development.

 

Here is a verbatim transcript of Vivin Mathew and Sriram Iyer’s comments on CNBC-TV18. Also watch the accompanying video.


 

The global financial crisis is proving to be a growth pill of sorts for the Indian pharma outsourcing sector. Companies like Merck of the US and Pfizer have already announced increased outsourcing of manufacturing and research and development activities to cut costs. After all, wages in India work out to around a fifth of wages in the west and there is no scarcity of patients for clinical trials.

 

Kewal Handa, MD, Pfizer said, “I think this should expedite the plans there to outsource more of research here. There is a lot of pressure on cost. Where do you get the advantage of doing research, in countries like India, China or Brazil, both in terms of research and manufacturing the products?”

 

India is the world's fifth largest active pharmaceutical ingredients manufacturing base.

 

A report shows India exported USD 1.7 billion worth of such products in 2007 and this is seen growing at 19% to USD 2.8 billion by 2010. India already has over US FDA-approved 100 plants -- the highest in any country outside the US.

 

Diana Anderson, President & CEO, D Anderson & Co said, “In 2008, US has outsourced more than 40% of its clinical trials and that is expected to increase to 65% by 2011.'

 

But the going could get tough. Experts say domestic drug companies have to expand capacity to make the most of this outsourcing wave. And a shortage of cheap credit may hurt these projects.

 

Sujay Shetty, PwC said, “The current crisis has made many PE firms and external investors very careful in investing. That is taking time for smaller firms to raise money. That could have some effect on capacity building and productivity.”

 

The global financial crisis is acting as a double-edged sword, as far as the pharma-outsourcing to India is concerned. While international drug-makers turn to India for cheaper resources for manufacturing and research, Indian companies have their work cut out for them, in terms of expanding capacities to grab these opportunities. Funds for clinical research and development are still harder to come by, as drug discovery is fraught with risks and failures. So there is a fear that the outsourcing wave may bypass India, for countries like Singapore and China.

 

CEO Wall See All

Harsh Manglik

Harsh Manglik

Chairman

Accenture India

Accenture India to hire aggressively for select verticals

Vishal Doshi

Vishal Doshi

Managing Director

Shrenju & Company

Shrenuj & Company will project 15% rev rise this yr

MP Taparia

MP Taparia

Chairman

Supreme Petrochemicals

Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs

Vineet Nayyar

Vineet Nayyar

Chief Executive Officer

HCL Technologies

HCL Tech plans to merge arms with itself, eyes new spots

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2010. All Rights Reserved